Summary: Despite their varied chemical structures and diverse origins—from synthesized LSD to traditional ayahuasca—major psychedelic compounds share a single, consistent pattern of brain activity. An international mega-analysis combined data from 11 datasets across five countries to uncover why chemically different psychedelics produce similar therapeutic and hallucinogenic effects.
The research shows that psychedelics reorganize brain function by weakening internal network cohesion and promoting unusual communication between systems that normally operate separately.
Key Facts
- The Mega-Analysis: Researchers analyzed more than 500 brain imaging sessions from 267 participants, overcoming the small-sample limits of individual studies driven by high costs and strict regulations.
- Network Breakdown: Under typical conditions, brain systems such as visual or emotional networks remain relatively modular. Psychedelics reduce those within-network connections, making these systems less rigid.
- The “Cross-Talk” Effect: While internal network strength declines, connectivity between different networks increases. This heightened global integration likely underlies experiences such as synesthesia and ego dissolution.
- The Common Fingerprint: For the first time, researchers demonstrated that psilocybin, LSD, mescaline, DMT and ayahuasca all produce this same two-part reorganization of brain circuits, regardless of their chemical differences.
- Regulatory and Therapeutic Value: The consistent neural signature provides a potential benchmark for regulators and researchers to evaluate psychedelic interventions and guide development of new treatments for mental health disorders.
Source: McGill University
Researchers have now shown that several major psychedelic drugs—psilocybin, LSD, mescaline, DMT and ayahuasca—produce a common pattern of brain activity despite their distinct pharmacologies.
An international consortium led by a McGill University team pooled resting-state brain imaging data from labs across five countries, producing the largest synthesis of psychedelic neuroimaging to date.
The findings, published in Nature Medicine, offer a clearer map of how psychedelics reshape large-scale brain organization and may inform future therapeutic approaches.
“This is a breakthrough in how we think about psychedelic drugs,” said Danilo Bzdok, Associate Professor in McGill’s Department of Biomedical Engineering and Canada CIFAR Artificial Intelligence Chair at Mila. “For the first time, we reveal a common denominator among substances previously treated as entirely separate.”
Two measurable changes in the brain
Although distinct psychedelics have shown promise for treating a range of mental health conditions, the neural basis for their shared effects was unclear. The mega-analysis identified two robust, reproducible changes induced by these drugs.
First, psychedelics tend to weaken connections within established brain networks. Under normal conditions, networks maintain tight internal communication that supports stable perception, cognition and emotion. Psychedelics make these networks less internally cohesive and less rigidly organized.
Second, psychedelics increase communication between normally separate networks, permitting signals to cross boundaries that are usually impermeable. This enhanced between-network connectivity — or “cross-talk” — may account for altered perceptions, unusual associations, and atypical sensory experiences reported during psychedelic states.
An ‘X-ray’ of global psychedelic research
The analysis integrated 11 independent datasets, totaling over 500 resting-state functional MRI sessions from 267 participants. Because individual psychedelic studies are often small—typically 10 to 30 participants—pooling across labs was necessary to reach statistically robust conclusions.
“By combining data from many sites, this approach gives us an X-ray view of the field,” said Bzdok, offering a more comprehensive and reliable perspective than any single-site study could provide.
The thawing of the ‘psychedelic research winter’
Interest in psychedelic-assisted therapies has resurged in recent years alongside improvements in brain imaging and a growing clinical literature. This revival contrasts with the “psychedelic research winter” that followed criminalization and cultural backlash in the 1970s.
“Many treatments for conditions like depression have changed little over decades,” Bzdok noted. “Psychedelics may represent one of the most significant shifts in mental health research since the late 20th century.”
By establishing a replicable neural signature of psychedelic action, this study aims to provide a practical benchmark for future research and to help address regulatory and logistical barriers that currently constrain large-scale investigations.
About the study
“An international mega-analysis of psychedelic drug effects on brain circuit function” by Manesh Girn and Danilo Bzdok et al. was published in Nature Medicine.
Key Questions Answered:
A: The large-scale reorganization—reduced within-network coherence and increased cross-network communication—appears consistent across drugs. However, the intensity and duration of those effects depend on how each substance interacts with specific serotonin receptors and other molecular targets. In other words, the drugs share a common neural “genre,” but each one produces a different “song.”
A: Not simply messier—more flexible. By weakening entrenched, habitual patterns of connectivity (which can be overactive in conditions like depression or obsessive-compulsive disorder), psychedelics may open a window for the brain to form new, healthier connections. This has been likened to a temporary “reset” of neural wiring.
A: Because a single lab faces legal and financial obstacles to studying multiple Schedule I substances. By pooling data across labs and countries, researchers created a high-resolution, cross-site view that reveals consistent patterns no individual study could reliably detect on its own.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was provided by staff editors.
About this psychopharmacology and neuroscience research news
Author: Keila DePape
Source: McGill University
Contact: Keila DePape – McGill University
Image: Image credit: Neuroscience News
Original Research: Open access. “An international mega-analysis of psychedelic drug effects on brain circuit function” by Manesh Girn, Manoj K. Doss, Leor Roseman, Katrin H. Preller, Fernanda Palhano-Fontes, Lorenzo Pasquini, Frederick S. Barrett, Pablo Mallaroni, Natasha L. Mason, Christopher Timmermann, Drummond E. McCulloch, Patrick M. Fisher, Brian S. Winston, Flora Moujaes, Felix Muller, Matthias E. Liechti, Franz X. Vollenweider, Johannes G. Ramaekers, Kim Kuypers, Draulio B. Araujo, Olaf Sporns, Joshua Siegel, Nico Dosenbach, David J. Nutt, Robin L. Carhart-Harris, Emmanuel A. Stamatakis & Danilo Bzdok. Nature Medicine. DOI: 10.1038/s41591-026-04287-9
Abstract
An international mega-analysis of psychedelic drug effects on brain circuit function
Psychedelic drugs are re-emerging as promising scientific and clinical tools. Despite rapid growth in clinical studies, the neural mechanisms underlying psychedelic effects have remained fragmented and sometimes inconsistent across independent reports.
To address this, the authors integrated 11 independent resting-state functional MRI datasets spanning five psychedelic compounds (psilocybin, lysergic acid diethylamide, mescaline, N,N-dimethyltryptamine and ayahuasca) from research groups across multiple countries. Using a consistent preprocessing pipeline and a Bayesian hierarchical modeling framework, the team identified shared alterations in brain function across drugs and sites.
Most notably, the analysis revealed increased functional connectivity between transmodal networks (including default mode, frontoparietal and limbic systems) and unimodal networks (visual and somatomotor), with specific subnetwork patterns. Key subcortical structures—such as the thalamus, caudate and putamen—and the cerebellum also showed altered coupling with sensorimotor networks.
Contrary to some single-site reports, Bayesian modeling indicated selective, weak-to-moderate reductions in within-network functional connectivity with considerable variability across drugs and networks. Overall, the results suggest that psychedelics reconfigure large-scale cortical organization while selectively engaging subcortical circuitry.
This synthesis offers the most comprehensive probabilistic map to date of how psychedelics alter brain organization and provides an empirical foundation to guide and benchmark future psychedelic neuroimaging research.